{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:58:32Z","timestamp":1791626312836,"version":"4.3.4"},"reference-count":78,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T00:00:00Z","timestamp":1572652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Proton pump inhibitors (PPIs) are recommended as a first-line treatment for gastroesophageal reflux disease (GERD) and other acid related disorders. In recent years, concerns have been raised about the increasing prevalence of patients on long-term PPI therapy and inappropriate PPI use. It is well known that short-term PPI therapy is generally well tolerated and safe; however, their extensive long-term use is a major global issue. One of these long-standing concerns is PPI-induced gastrin elevation secondary to hypoacidity. Hypergastrinemia is believed to play a role in rebound hyperacidity when PPIs are discontinued resulting in induced dyspeptic symptoms that might result in the reinstitution of therapy. Gastrin exerts tropic effects in the stomach, especially on enterochromaffin-like (ECL) cells, and concerns have also been raised regarding the potential progression to dysplasia or tumor formation following long-term therapy. It is well known that a substantial number of patients on long-term PPI therapy can discontinue PPIs without recurrence of symptoms in deprescribing trials. What is unknown is how sustainable deprescribing should be undertaken in practice and how effective it is in terms of reducing long-term outcomes like adverse drug events, morbidity and mortality. Moreover, there is no clear consensus on when and how deprescribing strategies should be attempted in practice. This review sought to summarize the harms and benefits of long-term PPI therapy with special focus on gastrin elevation and its relation to deprescribing studies and future interventions that may improve PPI use.<\/jats:p>","DOI":"10.3390\/ijms20215469","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T04:13:08Z","timestamp":1572840788000},"page":"5469","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":85,"title":["Problems Associated with Deprescribing of Proton Pump Inhibitors"],"prefix":"10.3390","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8688-449X","authenticated-orcid":false,"given":"Holmfridur","family":"Helgadottir","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland"},{"name":"Division of Gastroenterology and Hepatology, The National University Hospital of Iceland, 101 Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar S.","family":"Bjornsson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland"},{"name":"Division of Gastroenterology and Hepatology, The National University Hospital of Iceland, 101 Reykjavik, Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,11,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/MOG.0b013e328365efc7","article-title":"Gastric secretion","volume":"29","author":"Chu","year":"2013","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610100102","article-title":"Omeprazole: The first proton pump inhibitor","volume":"10","author":"Lindberg","year":"1990","journal-title":"Med. Res. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5056\/jnm.2013.19.1.25","article-title":"Pharmacokinetics and pharmacodynamics of the proton pump inhibitors","volume":"19","author":"Shin","year":"2013","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","article-title":"Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety","volume":"59","author":"Savarino","year":"2009","journal-title":"Pharmacol. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3748\/wjg.v13.i4.493","article-title":"Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion","volume":"13","author":"Cui","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1080\/00365520152584734","article-title":"The CCK-2 receptor is located on the ECL cell, but not on the parietal cell","volume":"36","author":"Bakke","year":"2001","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0140-6736(74)90869-1","article-title":"Inhibition of gastrin and gastric-acid secretion by growth-hormone release-inhibiting hormone","volume":"2","author":"Bloom","year":"1974","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/0016-5085(95)90571-5","article-title":"Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion","volume":"109","author":"Gedda","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1365-2036.2000.00829.x","article-title":"Proton pump inhibitors: Better acid suppression when taken before a meal than without a meal","volume":"14","author":"Hatlebakk","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000200509","article-title":"Role of gastrin as a trophic hormone","volume":"47","author":"Walsh","year":"1990","journal-title":"Digestion"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2036.2006.03084.x","article-title":"Discontinuation of proton pump inhibitors in patients on long-term therapy: A double-blind, placebo-controlled trial","volume":"24","author":"Bjornsson","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/01.md.0000236956.74128.76","article-title":"Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature","volume":"85","author":"Berna","year":"2006","journal-title":"Medicine (Baltimore)"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Helgadottir, H., Lund, S.H., Gizurarson, S., Metz, D.C., and Bjornsson, E.S. (2019). Predictors of Gastrin Elevation Following Proton Pump Inhibitor Therapy. J. Clin. Gastroenterol.","DOI":"10.1097\/MCG.0000000000001200"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00228-008-0538-y","article-title":"Proton pump inhibitors: An update of their clinical use and pharmacokinetics","volume":"64","author":"Shi","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1756284818777943","DOI":"10.1177\/1756284818777943","article-title":"Proton-pump inhibitors among adults: A nationwide drug-utilization study","volume":"11","author":"Halfdanarson","year":"2018","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/1756283X16650156","article-title":"Use of proton-pump inhibitors among adults: A Danish nationwide drug utilization study","volume":"9","author":"Pottegard","year":"2016","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/pds.1969","article-title":"Marked increase in proton pump inhibitors use in Australia","volume":"19","author":"Hollingworth","year":"2010","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ajg.2012.444","article-title":"Guidelines for the diagnosis and management of gastroesophageal reflux disease","volume":"108","author":"Katz","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_19","first-page":"S27","article-title":"Overutilization of proton pump inhibitors: A review of cost-effectiveness and risk [corrected]","volume":"104","author":"Heidelbaugh","year":"2009","journal-title":"Am. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1007\/s00228-010-0871-9","article-title":"Appropriateness of treatment recommendations for PPI in hospital discharge letters","volume":"66","author":"Ahrens","year":"2010","journal-title":"Eur J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11845-009-0426-1","article-title":"Inappropriate use of proton pump inhibitors","volume":"179","author":"Molloy","year":"2010","journal-title":"Ir. J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2036.2009.04092.x","article-title":"Clinical trial: Long-term use of proton pump inhibitors in primary care patients\u2014A cross sectional analysis of 901 patients","volume":"30","author":"Reimer","year":"2009","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1053\/j.gastro.2010.08.023","article-title":"Safety of proton pump inhibitor exposure","volume":"139","author":"Yang","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","article-title":"Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs","volume":"292","author":"Laheij","year":"2004","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/ajg.2012.179","article-title":"Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis","volume":"107","author":"Janarthanan","year":"2012","journal-title":"Am. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1345\/aph.1R174","article-title":"Proton pump inhibitor use and association with spontaneous bacterial peritonitis in patients with cirrhosis and ascites","volume":"46","author":"Siple","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","article-title":"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin","volume":"157","author":"Moayyedi","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1111\/j.1572-0241.2001.05345.x","article-title":"Acute interstitial nephritis due to omeprazole","volume":"96","author":"Myers","year":"2001","journal-title":"Am. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.hlc.2017.10.020","article-title":"Proton Pump Inhibitors and Cardiovascular Events: A Systematic Review","volume":"27","author":"Shiraev","year":"2018","journal-title":"Heart Lung Circ."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bundhun, P.K., Teeluck, A.R., Bhurtu, A., and Huang, W.Q. (2017). Is the concomitant use of clopidogrel and Proton Pump Inhibitors still associated with increased adverse cardiovascular outcomes following coronary angioplasty?: A systematic review and meta-analysis of recently published studies (2012\u20132016). BMC Cardiovasc. Disord., 17.","DOI":"10.1186\/s12872-016-0453-6"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/00365520903477348","article-title":"Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint","volume":"45","author":"Waldum","year":"2010","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/00365521.2016.1143527","article-title":"Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man?","volume":"51","author":"Waldum","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/j.cgh.2016.05.018","article-title":"Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis","volume":"14","author":"Spaetgens","year":"2016","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/apt.12012","article-title":"Gastric carcinoids after long-term use of a proton pump inhibitor","volume":"36","author":"Jianu","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/00365521.2011.627444","article-title":"Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor","volume":"47","author":"Jianu","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3109\/00365521.2015.1054426","article-title":"Gastric neuroendocrine neoplasms and proton pump inhibitors: Fact or coincidence?","volume":"50","author":"Cavalcoli","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e017739","DOI":"10.1136\/bmjopen-2017-017739","article-title":"Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden","volume":"7","author":"Brusselaers","year":"2017","journal-title":"BMJ Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/gutjnl-2017-314605","article-title":"Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study","volume":"67","author":"Cheung","year":"2018","journal-title":"Gut"},{"key":"ref_42","first-page":"568","article-title":"Omerprazole and other proton pump inhibitors: Pharmacology, efficacy, and safety, with special reference to use in children","volume":"27","author":"Israel","year":"1998","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_43","first-page":"354","article-title":"Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can. Fam. Physician."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"436","DOI":"10.5694\/mja18.00674","article-title":"Deprescribing proton pump inhibitors: Why, when and how","volume":"209","author":"Bytzer","year":"2018","journal-title":"Med. J. Aust."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1046\/j.1365-2036.2003.01593.x","article-title":"Short- and long-term therapy for reflux oesophagitis in the elderly: A multi-centre, placebo-controlled study with pantoprazole","volume":"17","author":"Pilotto","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000236025","article-title":"Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: A randomized controlled clinical trial","volume":"81","author":"Quartero","year":"2010","journal-title":"Digestion"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","article-title":"Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy","volume":"137","author":"Reimer","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/ajg.2010.81","article-title":"Dyspeptic symptom development after discontinuation of a proton pump inhibitor: A double-blind placebo-controlled trial","volume":"105","author":"Niklasson","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000321535","article-title":"Effect of proton-pump inhibitor therapy on serum chromogranin a level","volume":"84","author":"Pregun","year":"2011","journal-title":"Digestion"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"abstract S-308","DOI":"10.1016\/S0016-5085(19)37590-0","article-title":"Serum Concentration and Pharmacokinetics of Single and Repeated Oral Doses of Esomeprazole and Gastrin Elevation in Healthy Males and Females","volume":"156","author":"Helgadottir","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0016-5085(99)70118-6","article-title":"Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status","volume":"116","author":"Gillen","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.39.5.649","article-title":"Marked increase in gastric acid secretory capacity after omeprazole treatment","volume":"39","author":"Waldum","year":"1996","journal-title":"Gut"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004836-200109000-00007","article-title":"Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?","volume":"33","author":"Farup","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/00365521.2010.537684","article-title":"Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?","volume":"46","author":"Rydning","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/ajg.2011.220","article-title":"Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: Analysis of dexlansoprazole MR clinical trial data","volume":"106","author":"Metz","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1111\/j.1572-0241.2003.07665.x","article-title":"Step-down from multiple- to single-dose proton pump inhibitors (PPIs): A prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs","volume":"98","author":"Inadomi","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1053\/j.gastro.2009.05.015","article-title":"Evidence that proton-pump inhibitor therapy induces the symptoms it is used to treat","volume":"137","author":"McColl","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/apt.13324","article-title":"Systematic review: The effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology","volume":"42","author":"Lundell","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MCG.0000000000000542","article-title":"Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD: A Double-Blind Randomized Trial","volume":"51","author":"Helgadottir","year":"2017","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/fampra\/cmu050","article-title":"Strategies for discontinuation of proton pump inhibitors: A systematic review","volume":"31","author":"Haastrup","year":"2014","journal-title":"Fam. Pract."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/gut.25.9.957","article-title":"Optimal dose of oral omeprazole for maximal 24 h decrease of intragastric acidity","volume":"25","author":"Sharma","year":"1984","journal-title":"Gut"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/j.1365-2036.2004.01928.x","article-title":"Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: A randomized trial","volume":"19","author":"Krol","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_64","first-page":"463","article-title":"Factors influencing compliance in long-term proton pump inhibitor therapy in general practice","volume":"49","author":"Hungin","year":"1999","journal-title":"Br. J. Gen. Pract."},{"key":"ref_65","first-page":"CD011969","article-title":"Deprescribing versus continuation of chronic proton pump inhibitor use in adults","volume":"3","author":"Boghossian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bayerdorffer, E., Bigard, M.A., Weiss, W., Mearin, F., Rodrigo, L., Dominguez Munoz, J.E., Grundling, H., Persson, T., Svedberg, L.E., and Keeling, N. (2016). Randomized, multicenter study: On-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0448-x"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2036.2005.02413.x","article-title":"Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: On-demand treatment compared with continuous treatment","volume":"21","author":"Bour","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.curtheres.2005.08.012","article-title":"Effects of pantoprazole 20 mg in mildgastroesophageal reflux disease: Once-daily treatment in the acute phase, and comparison of on-demand versus continuous treatment in the long term","volume":"66","author":"Janssen","year":"2005","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.cgh.2011.11.021","article-title":"Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release","volume":"10","author":"Fass","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2036.2007.03248.x","article-title":"Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center","volume":"25","author":"Cote","year":"2007","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3748\/wjg.v17.i11.1480","article-title":"Proton pump inhibitor step-down therapy for GERD: A multi-center study in Japan","volume":"17","author":"Tsuzuki","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_72","first-page":"175436","article-title":"Placebo-Controlled Discontinuation of Long-Term Acid-Suppressant Therapy: A Randomised Trial in General Practice","volume":"2015","author":"Zwisler","year":"2015","journal-title":"Int. J. Fam. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gut.31.4.401","article-title":"Dyspepsia in England and Scotland","volume":"31","author":"Jones","year":"1990","journal-title":"Gut"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00365520510011579","article-title":"High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: A Kalixanda study report","volume":"40","author":"Ronkainen","year":"2005","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1572-0241.2003.07531.x","article-title":"Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association","volume":"98","author":"Shaker","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJM199510263331703","article-title":"A comparison of five maintenance therapies for reflux esophagitis","volume":"333","author":"Vigneri","year":"1995","journal-title":"N Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/j.1572-0241.2004.30228.x","article-title":"Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett\u2019s esophagus","volume":"99","author":"Aguirre","year":"2004","journal-title":"Am. J. Gastroenterol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 Years of Proton Pump Inhibitors: A Comprehensive Review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/21\/5469\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:31:28Z","timestamp":1760189488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/21\/5469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,2]]},"references-count":78,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["ijms20215469"],"URL":"https:\/\/doi.org\/10.3390\/ijms20215469","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,2]]}}}